Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease: The Hisayama Study

Atherosclerosis

Volumn 231, Issue 2, 2013, Pages 261-267

  Ninomiya, Toshiharu ^a   Nagata, Masaharu ^a   Hata, Jun ^a   Hirakawa, Yoichiro ^a   Ozawa, Mio ^a   Yoshida, Daigo ^a   Ohara, Tomoyuki ^a   Kishimoto, Hiro ^a   Mukai, Naoko ^a   Fukuhara, Masayo ^a   Kitazono, Takanari ^a   Kiyohara, Yutaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Cardiovascular disease; Eicosapentaenoic acid; High sensitivity C reactive protein; Prospective cohort study

Indexed keywords

ARACHIDONIC ACID; C REACTIVE PROTEIN; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; JAPANESE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL;

AA; ARACHIDONIC ACID; CARDIOVASCULAR DISEASE; CI; CONFIDENCE INTERVAL; DHA; DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; EPA; HAZARD RATIO; HDL; HIGH SENSITIVITY C-REACTIVE PROTEIN; HIGH-DENSITY LIPOPROTEIN; HIGH-SENSITIVITY C-REACTIVE PROTEIN; HR; HS-CRP; POLYUNSATURATED FATTY ACID; PROSPECTIVE COHORT STUDY; PUFA;

ADULT; AGED; ARACHIDONIC ACID; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; EICOSAPENTAENOIC ACID; FATTY ACIDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84888081196     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.09.023     Document Type: Article

References (42)

1. Bang H.O., Dyerberg J. Plasma lipids and lipoproteins in greenlandic west coast eskimos. Acta Med Scand 1972, 192:85-94.
2. Bang H.O., Dyerberg J., Nielsen A.B. Plasma lipid and lipoprotein pattern in greenlandic west-coast eskimos. Lancet 1971, 1:1143-1145.
3. Kromhout D., Bosschieter E.B., de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. NEngl J Med 1985, 312:1205-1209.
4. Kromhout D., Feskens E.J., Bowles C.H. The protective effect of a small amount of fish on coronary heart disease mortality in an elderly population. Int J Epidemiol 1995, 24:340-345.
5. Norell S.E., Ahlbom A., Feychting M., Pedersen N.L. Fish consumption and mortality from coronary heart disease. BMJ 1986, 293:426.
6. Rissanen T., Voutilainen S., Nyyssonen K., Lakka T.A., Salonen J.T. Fish oil-derived fatty acids, docosahexaenoic acid and docosapentaenoic acid, and the risk of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study. Circulation 2000, 102:2677-2679.
7. Daviglus M.L., Stamler J., Orencia A.J., et al. Fish consumption and the 30-year risk of fatal myocardial infarction. NEngl J Med 1997, 336:1046-1053.
8. Hu F.B., Bronner L., Willett W.C., et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAm Med Assoc 2002, 287:1815-1821.
9. Iso H., Kobayashi M., Ishihara J., et al. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-based (JPHC) Study Cohort I. Circulation 2006, 113:195-202.
10. Wang C., Harris W.S., Chung M., et al. N-3 fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr 2006, 84:5-17.
11. Marik P.E., Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009, 32:365-372.
12. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
13. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin e after myocardial infarction: results of the GISSI-Prevenzione Trial. Gruppo Italiano per lo Studio della sopravvivenza nell'Infarto miocardico. Lancet 1999, 354:447-455.
14. Tavazzi L., Maggioni A.P., Marchioli R., et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF Trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230.
15. Singh R.B., Niaz M.A., Sharma J.P., Kumar R., Rastogi V., Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival-4. Cardiovasc Drugs Ther 1997, 11:485-491.
16. Burr M.L., Fehily A.M., Gilbert J.F., et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989, 2:757-761.
17. Calder P.C. The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Mol Nutr Food Res 2012, 56:1073-1080.
18. Adkins Y., Kelley D.S. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. JNutr Biochem 2010, 21:781-792.
19. Itakura H., Yokoyama M., Matsuzaki M., et al. Relationships between plasma fatty acid composition and coronary artery disease. JAtheroscler Thromb 2011, 18:99-107.
20. Kubo M., Kiyohara Y., Kato I., et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama Study. Stroke 2003, 34:2349-2354.
21. Maebuchi D., Arima H., Ninomiya T., et al. Arterial stiffness and qt interval prolongation in a general population: the Hisayama Study. Hypertens Res 2008, 31:1339-1345.
22. Ozawa A., Takayanagi K., Fujita T., et al. Determination of long chain fatty acids in human total plasma lipids using gas chromatography. Jpn Analyst 1982, 31:87-91. [in Japanese], cited by. https://www.jstage.jst.go.jp/article/bunsekikagaku1952/31/2/31_2_87/_article/-char/en/.
23. Thygesen K., Alpert J.S., White H.D. Joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007, 28:2525-2538.
24. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
25. Arima H., Kubo M., Yonemoto K., et al. High-sensitivity c-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama Study. Arterioscler Thromb Vasc Biol 2008, 28:1385-1391.
26. Iso H., Sato S., Folsom A.R., et al. Serum fatty acids and fish intake in rural Japanese, urban Japanese, Japanese American and Caucasian American men. Int J Epidemiol 1989, 18:374-381.
27. Siscovick D.S., Raghunathan T.E., King I., et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAm Med Assoc 1995, 274:1363-1367.
28. Albert C.M., Campos H., Stampfer M.J., et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. NEngl J Med 2002, 346:1113-1118.
29. Lemaitre R.N., King I.B., Mozaffarian D., Kuller L.H., Tracy R.P., Siscovick D.S. n-3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the Cardiovascular Health Study. Am J Clin Nutr 2003, 77:319-325.
30. Hagi A., Nakayama M., Shinzaki W., Haji S., Ohyanagi H. Tissue n-3 and n-6 fatty acids and risk for coronary heart disease events. Atherosclerosis 2007, 193:1-10.
31. Hagi A., Nakayama M., Shinzaki W., Haji S., Ohyanagi H. Effects of the omega-6:omega-3 fatty acid ratio of fat emulsions on the fatty acid composition in cell membranes and the anti-inflammatory action. JPEN J Parenter Enteral Nutr 2010, 34:263-270.
32. Kwak S.M., Myung S.K., Lee Y.J., Seo H.G. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012, 172:686-694.
33. Bosch J., Gerstein H.C., Dagenais G.R., et al. n-3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. NEngl J Med 2012, 367:309-318.
34. Roncaglioni M.C., Tombesi M., Avanzini F., et al. n-3 Fatty acids in patients with multiple cardiovascular risk factors. NEngl J Med 2013, 368:1800-1808.
35. Lewis R.A., Austen K.F., Soberman R.J. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. NEngl J Med 1990, 323:645-655.
36. Tagawa H., Shimokawa H., Tagawa T., Kuroiwa-Matsumoto M., Hirooka Y., Takeshita A. Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilatation in patients with coronary artery disease. JCardiovasc Pharmacol 1999, 33:633-640.
37. De Caterina R., Cybulsky M.I., Clinton S.K., Gimbrone M.A., Libby P. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb 1994, 14:1829-1836.
38. Amano T., Matsubara T., Uetani T., et al. Impact of omega-3 polyunsaturated fatty acids on coronary plaque instability: an integrated backscatter intravascular ultrasound study. Atherosclerosis 2011, 218:110-116.
39. Thies F., Garry J.M., Yaqoob P., et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003, 361:477-485.
40. Cawood A.L., Ding R., Napper F.L., et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 2010, 212:252-259.
41. Nakakuki M., Kawano H., Notsu T., Imada K. Eicosapentaenoic acid suppresses palmitate-induced cytokine production by modulating long-chain acyl-CoA synthetase 1 expression in human THP-1 macrophages. Atherosclerosis 2013, 227:289-296.
42. Lee S.H., Shin M.J., Kim J.S., et al. Blood eicosapentaenoic acid and docosahexaenoic acid as predictors of all-cause mortality in patients with acute myocardial infarction - data from Infarction Prognosis Study (IPS) registry. Circ J 2009, 73:2250-2257.